Objectives Our objective was to evaluate the impact of serum IgA level on the clinical presentation and severity of adult IgA vasculitis (IgAV).
Methods We prospectively collected data on newly diagnosed histologically proven adult IgAV cases between January 2013 and December 2015 at our at our secondary/tertiary rheumatology centre. Patients were stratified according to the serum level of IgA into two groups (elevated IgA (>4.10 g/l) vs. normal IgA (0.7–4.10 g/l)).
Results During the 36 month observation period, 92 new adult IgAV cases (54% male) were identified. The median age was 65.8 (interquartile range (IQR) 48.7–77.3, range 19–88) years and the median disease duration (IQR, range) 7 (6–21, 2–120) days. The serum level of IgA was elevated in 39 (42.4%) cases. The characteristics of IgAV groups with increased and with normal serum IgA level at presentation and at follow-up are presented in Table 1. Follow-up data were available for 59 (24 had elevated IgA) patients, with a median (IQR) follow-up of 7.2 (5.0–14.5) months.
Conclusions Elevated IgA serum level does not seem to have any significant impact on the disease manifestations and severity of adult IgAV. However, there was a trend toward less frequent antecedent infections and more frequent malignancy development in the group with high serum IgA.
Disclosure of Interest None declared